Who we are
Takeda Oy is the Finnish marketing and sales organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. As the largest pharmaceutical company in Japan, and one of the global leaders in the industry, Takeda is committed to striving for better health for people worldwide, through leading innovation in medicine. Takeda has been transforming itself through strategic acquisitions, broadening its therapeutic expertise and geographic reach. The company now has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and the fast-growing emerging markets, including Latin America, Russia-CIS and China. Our focus areas are central nervous system, speciality cardiovascular, gastroenterology, oncology and vaccines.
Our parent company, Takeda Pharmaceuticals is a research-based global company with its main focus on pharmaceuticals. Takeda has global manufacturing, development activities and a marketing and sales network for its products in more than 70 markets. Today, our new global portfolio strengthens Takeda’s presence as a speciality care provider, with new corporate products in the areas of gastroenterology ( Crohn´s disease, Colitis ulcerosa), oncology (Hodgkin lympfoma) and haematology (multiple myeloma). Furthermore, Takeda is looking for new ways to broaden patient access to our new therapies and, through digitalization, looking to develop valuable support applications for therapy monitoring.
In Finland, Takeda Oy is one of the leading top 10 local pharma marketing and sales companies for proprietary products in both the prescription and self-medication segments. Our aim is to ensure that patients in Finland will have equal access on highly innovative products on areas with unmet medical needs. In Finland Takeda also conducts a large number of clinical trials together with healthcare professionals for our strategic products in selected therapy areas.
The local healthcare providers, academic health institutions, bio-banks and health professionals together with patients will gain science benefit, new treatment access and clinical experience from the most recent drug therapy advances in our pipeline on Takeda´s focus disease areas.
What we are looking for
Takeda is looking for new co-operative models and new partnership activities to carry out research in the clinical trial setting with our products. Decisions on new co-operation with potential partners are made at Takeda’s Group level.
We want to highlight to our potential new partners and Takeda´s global R&D function that Finland is the most advanced test-bed in the world - especially regarding digital health data, genomics and biomarkers. This excellent test-bed environment will accelerate our R&D projects' timelines and final outputs, and enables better future medicine targeting as new biomarkers are developed.
Takeda Finland also wants to be a true, real world data excellence center by leveraging our Finnish clinical biobanks for real world data and evidence to support our business planning and partnership projects.